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ABSTRACT: The potential long-term consequences
of treatments delaying manifestations of neurodegener-
ative diseases have not been explored. Using Hunting-
ton disease (HD) data and Markov chain Monte Carlo
methods, we simulated the effects of therapies with
equivalent effects on time to onset of HD and survival
with HD. Our results suggest substantial potential
trade-offs in effects of these therapies; significant
delays in time to onset of HD were accompanied by
significant prolongations of survival after onset of HD.
Under a variety of assumptions, treatments delaying
onset of HD result in some patients likely to have a
greater increase in survival with manifest HD compared
to delays in time to onset of HD. Our results suggest
that future work in HD should be sensitive to the poten-
tial existence of such trade-offs and that understanding
the preferences of HD patients and the broader HD
community will be increasingly important. Future
research, trial design, and treatment strategies in HD
and other mid-life-onset neurodegenerative disorders
should consider the possibility of trade-offs in long-term
consequences of disease-modifying treatments. VC 2015
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Disease-modifying treatments for mid- to late-life-
onset neurodegenerative disorders may become a real-
ity in the near future. There has been little effort to
study the potential long-term consequences of such
treatments, particularly therapies that delay the onset
of conversion to manifest disease. Huntington disease
(HD) is a mid-life-onset dominant polyglutamine dis-
order with virtually complete penetrance, easily identi-
fied mutant allele carriers, good ability to predict age
of conversion to manifest disease state, and reasonably
well-defined natural history.1,2 HD is an excellent tar-
get for treatments delaying onset of manifest disease
and the subject of vigorous preclinical and clinical
therapeutic research. Though considerable attention
has been paid to characterizing the premanifest period
and the clinical features of manifest disease progres-
sion, relatively little attention has been paid to poten-
tial consequences of effective HD treatments.
Preclinical research suggests that disease-modifying
therapies based on suppression of mutant huntingtin
gene expression are a viable treatment approach.3-5
Some of these therapies are now entering initial clini-
cal trials.
Efficacious disease-modifying therapies for HD,
however, may entail trade-offs. An effective disease-
modifying treatment might plausibly both delay both
onset of manifest HD and slow progression of HD,
potentially leading to increased survival of HD
patients. Though delaying HD onset is undoubtedly
desirable, increased survival with HD is not necessar-
ily a desirable outcome for patients and their families.
The potential existence of trade-offs between clearly
desirable and potentially undesirable treatment effects
suggests that patient-centered decision making is
important in presymptomatic HD treatment.6 Optimal
decision procedures require understanding of patient
and family values, and how treatments affect out-
comes of interest to patients and their families. If such
------------------------------------------------------------
*Correspondence to: Dr. Roger L. Albin, Department of Neurology, Uni-
versity of Michigan, 5023 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI,
48109-2200, USA; ralbin@umich.edu
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online ver-
sion of this article.
Received: 2 March 2015; Revised: 16 April 2015; Accepted: 1 June
2015
Published online 14 July 2015 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.26318
V I E W P O I N T
Movement Disorders, Vol. 30, No. 10, 2015 1319
trade-offs exist, presymptomatic HD treatment deci-
sions will necessitate a deliberative shared decision-
making approach more similar to decisions to undergo
genetic testing for HD than the decision to take an
aspirin after a heart attack. With significant treatment
experiments now underway, this is an appropriate
time to address these issues, particularly given that
some promising treatments may produce lasting
effects.5 Outcomes of interest to potential patients
need to be enumerated now and trials designed to
capture these outcomes.
To explore potential consequences of effective
disease-modifying treatments of HD, we employed
simulation methods and the best available data to esti-
mate the effects of applying a hypothetically effective
HD disease-modifying treatment that affects time to
onset of manifest disease and survival duration after
disease onset in a realistic premanifest trial popula-
tion. Formal modeling has the virtue of requiring
explicit specification of crucial assumptions, facilitat-
ing identification of important questions related to
treatment development.
Simulation Model
We used Markov chain Monte Carlo (MCMC)
methods to build a simple simulation model to explore
the impact of therapies with specified effect sizes on
time to onset of HD and survival with HD (Fig. 1).
To this end, we first developed a simulated population
of 10,000 premanifest HD patients with normal age
(mean542; standard deviation [SD]510) and repeat
length (mean542.5; SD52.4). These distributions
are based on data from the Predict-HD study and
assume that trial populations would be relatively simi-
lar to this population.7 Time to manifest HD was esti-
mated for each individual using the Langbehn et al.
model for predicting HD onset based on age at enroll-
ment and repeat length.1 Time with HD was estimated
by randomly drawing from a normal distribution
(mean5 21; SD512) based on data from the
National Research Roster for HD Patients and Fami-
lies.2 Because these data show that patients with
juvenile-onset HD have less time with HD than
patients with adult-onset HD, we dropped individuals
from the simulated population with age less than 20.
The initial model instantiated the following
assumptions:
1. An effective treatment reduced both time to HD
(HR1) and time with (HR2) HD with equal rela-
tive effects.
2. The effective treatment does not change the clini-
cal features of manifest HD, that is, HD has the
same behavioral, cognitive, and motor deficits
found presently in HD patients.
3. The model does not include competing causes of
mortality; model subjects die only from HD.
4. The model population has the features of the
PREDICT-HD study population.
To account for uncertainty in both time to HD and
time with HD, we repeatedly sampled from the joint
parameter space using MCMC sampling implemented
through JAGS and R (R Core Team [2014]; R: A lan-
guage and environment for statistical computing; R
Foundation for Statistical Computing, Vienna, Austria;
http://www.R-project.org/).8 Sampling was repeated
with the assumption that patients received an effective
treatment that reduced both time to HD (HR1) and
time with HD (HR2) with a hazard ratio (HR) of 0.8.
Descriptive statistics were used to summarize the sim-
ulation results. To explore outcomes assuming thera-
pies were more effective at delaying onset of HD than
extending life with HD, sensitivity analysis was per-
formed subsequently by repeating the primary analysis
while holding the treatment effect for time to HD con-
stant (HR1) and decreasing the treatment effect for
time with HD (HR2).
FIG. 1. MCMC model of HD progressions. HR1: treatment effect/HR of hypothetical treatment on time to HD. HR2: treatment effect/HR of hypothet-
ical treatment on time with HD.
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Simulation Results
Before considering treatment effects, from our model
we estimate that 69% of plausible candidates for a
premanifest HD trial are likely to live a longer frac-
tion of their remaining lives with manifest HD. Simu-
lation results are stratified into quintiles on the basis
of estimated time to onset of HD. For individuals in
the first quintile of time to HD (mean age: 52; mean
repeat length: 44), we estimate an expected 2.7 years
of time to onset of HD, compared to 21 years of
time with HD. Individuals in the fifth quintile of time
to HD are estimated to have almost 33 years of time
to onset of HD, compared to 21 years of time with
HD (Table 1). Assuming that subjects receive a treat-
ment with similar relative effects on time to onset of
HD and time with HD (HR, 0.8 for both), the overall
mean gain in time to onset of HD is 2.7 years (SD,
2.9) and the overall mean gain in time with HD is 5.3
years (SD, 3.0). Individuals in the first quintile of time
to onset of HD are modeled to gain approximately 8
months in time to onset of HD versus 5 years in time
with HD. Individuals in the fifth quintile of time to
HD would gain 8 years in time to onset of HD versus
5 years in time with HD.
With sensitivity analysis, as the treatment effect on
survival with HD was reduced with treatment effect
of time to onset of HD unchanged, there was an
expected decrease in survival with HD. Even for a
treatment with a relatively disparate effect on time to
onset of (HR, 0.80) compared to time with HD (HR,
0.95), however, approximately 40% of patients
treated in this model population would experience
greater increases in survival with HD than delays in
HD onset (Table 2).
Discussion
Our results suggest significant trade-offs accompany-
ing effective disease-modifying treatments for HD. In
our simulations, delaying onset of HD was accompa-
nied often by larger extensions of time with HD in a
substantial fraction of this simulated patient popula-
tion. These results suggest that unless effective disease-
modifying therapies have no effect on extending HD
survival, effective treatment may be accompanied by
potentially undesirable consequences of extending time
with HD in a sizable proportion of treated patients
and also of increasing HD prevalence.
In terms of designing disease-modifying trials for
HD, our simulation results suggest that attention
should be paid to assessing treatment effects on both
time to onset of HD and progression of HD. Accumu-
lating data in both premanifest and manifest HD sub-
jects will be necessary to fully gauge the consequences
of HD treatments. Trials aiming to modify onset of
HD should incorporate long-term follow-up in at least
a subset of subjects. Serial randomization using
SMART clinical trials designs (e.g., rerandomizing at
onset of HD) might be considered to measure the
TABLE 1. Primary simulation results
Quintiles of Time to HD
1 2 3 4 5
Age, mean years (SD) 52.3 (7.0) 45.6 (6.8) 41.4 (6.8) 38.0 (7.8) 34.9 (7.9)
Repeat length, mean years (SD) 44.8 (1.8) 43.5 (1.7) 42.7 (1.6) 41.8 (1.6) 39.8 (1.7)
Time to HD, mean years (SD) 2.7 (0.4) 5.4 (1.2) 10.7 (1.9) 18.0 (2.5) 32.6 (9.1)
Time with HD, mean years (SD) 20.8 (11.7) 21.0 (11.8) 21.2 (12.4) 20.9 (11.6) 21.1 (12.0)
% of survival with HD, mean years (SD) 85.7 66.2 59.8 46.2 36.1
Increase in time to HD on treatment, mean years (SD) 0.7 (0.1) 1.4 (0.3) 2.7 (0.5) 4.5 (0.6) 8.1 (2.3)
Increase in time with HD on treatment, mean years (SD) 5.2 (2.9) 5.3 (2.9) 5.3 (3.1) 5.2 (2.9) 5.3 (3.0)
Baseline characteristics of the simulated population and time to and with HD as well as increase in time to and with HD with a treatment equally effective at
increasing both (HR, 0.8).
TABLE 2. Sensitivity analysis
Quintiles of Time to HD
HR for Survival With HD 1 2 3 4 5
Increase in time to HD on treatment, mean years (SD) 0.7 (0.1) 1.4 (0.3) 2.7 (0.5) 4.5 (0.6) 8.1 (2.3)
Increase in time with HD on treatment, mean years (SD) 0.80 5.2 (2.9) 5.3 (2.9) 5.3 (3.1) 5.2 (2.9) 5.3 (3.0)
Increase in time with HD on treatment, mean years (SD) 0.85 3.7 (2.1) 3.7 (2.1) 3.7 (2.2) 3.7 (2.1) 3.7 (2.1)
Increase in time with HD on treatment, mean years (SD) 0.90 2.3 (1.3) 2.3 (1.3) 2.4 (1.4) 2.3 (1.3) 2.3 (1.3)
Increase in time with HD on treatment, mean years (SD) 0.95 1.1 (0.6) 1.1 (0.6) 1.1 (0.7) 1.1 (0.6) 1.1 (0.6)
Assuming that a treatment has a constant effect on the time to HD (HR, 0.8; top row), the increase in time with HD is shown with decreasing effect sizes on
survival with HD as the HR increases from 0.80 to 0.95.
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effects of therapies on time to HD and time with
HD.9
Given the possibility that effective disease-modifying
treatments will prolong survival of HD, our results sug-
gest that increased attention should be devoted to devel-
oping effective treatments for disabling clinical features
of HD, such as its psychiatric and cognitive impair-
ments, particularly given the prevalence of problematic
psychiatric symptoms in some patients with mild HD. It
may be the case that effective presymptomatic therapies
would reduce disease severity with manifest HD. partic-
ularly given the prevalence of problematic psychicatric
symptoms in some patients with mild HD. Conse-
quently, potential treatments that delay disease onset
and ameliorate important clinical features of manifest
HD would be particularly desirable and attention
should be paid to beneficial symptomatic effects of
potentially disease-modifying interventions in trials.
Our modeling approach is admittedly simple and
has several limitations. It is plausible, however, that
our primary conclusion—trade-offs between delays to
HD onset and survival with HD—would be obtained
under a variety of assumptions. The most limiting
assumptions of our approach are that successful dis-
ease modifying therapies will affect time to onset of
HD and survival with HD equally. The primary path-
ogenic process(es) in HD may trigger self-sustaining
secondary pathological cascades that drive progression
of manifest disease. Cysteine-adenine-guanine (CAG)
repeat number strongly influences age of onset of HD,
but its relationship to manifest disease progression is
controversial with some analyses describing only a
weak relationship (for concise review, see Ravina
et al.).10 These results are consistent with dissociation
of processes driving onset of HD and progression of
HD. Analysis of CARE-HD trial data, however, indi-
cates that CAG repeat number, a major determinant
of age of onset of manifest HD, is also a significant
driver of disease progression.10 This result is consistent
with underlying uniformity of processes determining
age of HD onset and speed of HD progression. Our
sensitivity analyses explored decoupling of processes
driving onset of and progression of HD. In simulations
modeling treatments with significantly larger effects in
delaying onset of HD than slowing progression of
HD, a substantial number of simulated patients expe-
rienced greater prolongation of survival with HD than
delay in onset of HD.
Another potential limitation of our model is that we
do not correct for competing causes of mortality. In
this relatively young projected population, competing
mortality effects should be negligible, but with sub-
stantial delays in age of onset of manifest HD, com-
peting causes of mortality may remove patients from
the population preceding HD onset. This effect would
constitute a virtual cure and was observed in simu-
lated subjects with the largest effects of treatment in
delaying onset of HD (Table 1, quintile 5); those who
were farthest from onset of manifest HD at time of
treatment initiation. These results may inform use of
an effective treatment. An intuitively attractive corol-
lary is that earlier treatment is better, suggesting that
treatment should be initiated in early adult life. This
potential treatment strategy demands effective thera-
pies with excellent tolerability for decades, and given
that it would be applied in healthy individuals, will
have to possess low toxicities. A more radical poten-
tial implication is that a rational treatment strategy
would be to treat until onset of manifest disease, then
cease treatment. It is possible as well that interven-
tions delaying onset and prolonging survival of mani-
fest HD could “buy time” for affected individuals
while effective symptomatic therapies are developed.
Most important, our simulation results indicate the
presence of significant trade-offs in the development
and application of disease-modifying treatments for
HD. The potential existence of undesirable effects on
HD survival and prevalence suggest that more effort
should be devoted to defining the criteria for successful
treatment of HD. Though delaying onset to manifest
HD is certainly an unalloyed good, presymptomatic
treatments may have less obviously positive consequen-
ces, such as increased survival with HD, institutionali-
zation, resource use, and prevalence. Though
discussions of this kind are informed by scientific
assessments, this is not a scientific problem. Discus-
sions about the criteria for successful treatments for
HD confront potentially difficult questions of values
and quality of life. These discussions must focus on
patients with manifest HD, premanifest HD mutant
allele carriers, and the unaffected family members who
bear the burden of caring for HD patients. It will be
crucial to understand the preferences of these individu-
als with respect to the possible trade-offs that arise
from presymptomatic HD treatment. The HD research
community should take the lead in initiating these
essential discussions and developing the patient-
centered shared decision-making strategies necessary to
optimize decisions in the context of trade-offs. This is
an opportunity for the HD community to establish
standards to guide the adoption of treatments, rather
than passively accept the consequences of novel tech-
nologies. Given that similar issues will likely arise for
presymptomatic disease-modifying therapies for other
neurodegenerative disorders, this opportunity has to
the potential to establish procedures of broad utility to
the larger biomedical research community.
References
1. Langbehn DR, Brinkman RR, Falush D, et al. A new model for
prediction of the age of onset and penetrance for Huntington’s dis-
ease based on CAG length. Clin Genet 2004;65:267-277.
A L B I N A N D B U R K E
1322 Movement Disorders, Vol. 30, No. 10, 2015
2. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in dura-
tion of Huntington’s disease based on age at onset. J Neurol Neu-
rosurg Psychiatr 1999;66:52-56.
3. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and
motor dysfunction in a conditional model of Huntington’s disease.
Cell 2000;101:57-66.
4. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained
therapeutic reversal of Huntington’s disease by transient repression
of huntingtin synthesis. Neuron 2012;74:1031-1044.
5. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda
SR, Davidson BL. Preclinical safety of RNAi-mediated HTT sup-
pression in the rhesus macaque as a potential therapy for Hunting-
ton’s disease. Mol Ther 2011;19:2152-2162.
6. Barry M J, Edgman-Levitan, S. Shared decision making—pinnacle
of patient-centered care. N Engl J Med 2012;366:780-781.
7. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive
clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-
890.
8. Plummer M. JAGS: a program for analysis of Bayesian graphical
models using Gibbs sampling. In: Hornik K, Leisch F, Zeileis A,
eds. Proceedings of the 3rd International Workshop on Distributed
Statistical Computing (DSC 2003). Vienna: Austrian Association
for Statistical Computing and the R Foundation for Statistical
Computing; 2003.
9. Almirall D, Compton SN, Gunlicks-Stoessel M, et al. Designing a
pilot sequential multiple assignment randomized trial for develop-
ing an adaptive treatment strategy. Statist Med 2012;31:1887-
1902.
10. Ravina B, Romer M, Constantinescu R, et al. The relationship
between CAG repeat length and clinical progression in Hunting-
ton’s disease. Mov Disord 2008;23:1223-1227.
H D T R E A T M E N T T R A D E - O F F S
Movement Disorders, Vol. 30, No. 10, 2015 1323
